News
  Date Title View
Apr 18, 2018
BURLINGTON, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the key results from the previously completed pivotal Phase 3 study evaluating ZILRETTA (triamcinolone acetonide extended-release injectable suspension) have been published in the print and online edition of the ...
Apr 6, 2018
BURLINGTON, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to four new employees for an aggregate of 12,300 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an effective date of April 2, 20...
Mar 19, 2018
BURLINGTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at Needham & Company's 17th Annual Healthcare Confer...
Mar 8, 2018
Early launch activities for ZILRETTA® progressing well (strong clinical interest from prescribers; broad coverage from payers; encouraging feedback from patients)   Company booked net ZILRETTA sales of approximately $355K in Q4 Encouraging initial resul...
Mar 7, 2018
BURLINGTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) will be presenting at the Cowen 38th Annual Health Care Conference in Boston, Massachusetts. Michael Clayman, M.D., President and Chief Executive Officer, is scheduled to present at 10:40 a.m. Eastern Time on Wednesday, March 14, 2018....
Mar 6, 2018
Post-hoc analysis demonstrates potential of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) to provide effective pain relief regardless of prior intra-articular corticosteroid useEffects of ZILRETTA show improvement on health-related quality of life in pati...
Mar 2, 2018
BURLINGTON, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to two new employees for an aggregate of 4,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an effective date of March 1, 2018...
Feb 28, 2018
BURLINGTON, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Florida. Dr. Clayman is scheduled to present at 8...
Feb 26, 2018
BURLINGTON, Mass., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth quarter and full year 2017 financial results after the close of the U.S. financial markets on Thursday, March 8, 2018. Flexion's management will host a conference call at 4:30 p.m. ET to ...
Feb 14, 2018
BURLINGTON, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, and Dan Deardorf, Senior Vice President, Commercial Operations, will participate in a fireside chat at the RBC Capital Markets 2018 Global Healthcare Con...
1
... NextLast
= add release to Briefcase